Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.
Genelux Corporation (NASDAQ: GNLX), un'azienda immuno-oncologica in fase clinica avanzata, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York, il 7 e 8 maggio 2025. Il CEO e Presidente Thomas Zindrick e il CFO Matt Pulisic parteciperanno a una conversazione informale con Silvan Tuerkcan, Managing Director di Biotech Equity Research, l'8 maggio alle 13:30 ET. Il dibattito verterà sui programmi clinici dell'azienda e sulle prossime tappe fondamentali.
L'evento sarà accessibile tramite webcast, con una replica disponibile per 90 giorni sulla pagina IR di Genelux. Durante la conferenza, l'azienda terrà anche incontri individuali con investitori istituzionali.
Genelux Corporation (NASDAQ: GNLX), una empresa de inmunooncología en etapa clínica avanzada, ha anunciado su participación en la próxima Citizens Life Sciences Conference en Nueva York, los días 7 y 8 de mayo de 2025. El CEO y presidente Thomas Zindrick y el CFO Matt Pulisic participarán en una charla informal con Silvan Tuerkcan, Director General de Biotech Equity Research, el 8 de mayo a la 1:30 p.m. ET. La discusión se centrará en los programas en etapa clínica de la empresa y los próximos hitos.
El evento estará disponible vía webcast, con una repetición accesible durante 90 días en la página de relaciones con inversores de Genelux. La empresa también llevará a cabo reuniones individuales con inversores institucionales durante la conferencia.
Genelux Corporation (NASDAQ: GNLX)는 후기 임상 단계 면역종양학 회사로서, 2025년 5월 7일부터 8일까지 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여할 예정임을 발표했습니다. CEO 겸 회장인 Thomas Zindrick와 CFO Matt Pulisic는 5월 8일 오후 1시 30분(동부시간)에 Biotech Equity Research의 전무이사 Silvan Tuerkcan과 함께 파이어사이드 채팅을 진행할 예정입니다. 이번 대화는 회사의 임상 단계 프로그램과 다가오는 주요 일정에 초점을 맞출 것입니다.
이 행사는 웹캐스트로 시청 가능하며, 다시보기 영상은 Genelux의 IR 페이지에서 90일간 제공됩니다. 또한, 회사는 컨퍼런스 기간 동안 기관 투자자들과 일대일 미팅도 진행할 예정입니다.
Genelux Corporation (NASDAQ : GNLX), une société d'immuno-oncologie en phase clinique avancée, a annoncé sa participation à la prochaine Citizens Life Sciences Conference à New York, les 7 et 8 mai 2025. Le PDG et président Thomas Zindrick ainsi que le directeur financier Matt Pulisic participeront à une discussion informelle avec Silvan Tuerkcan, directeur général de Biotech Equity Research, le 8 mai à 13h30 ET. La discussion portera sur les programmes cliniques de la société et les prochaines étapes importantes.
L'événement sera accessible via webcast, avec une rediffusion disponible pendant 90 jours sur la page IR de Genelux. La société organisera également des réunions individuelles avec des investisseurs institutionnels lors de la conférence.
Genelux Corporation (NASDAQ: GNLX), ein Immunonkologie-Unternehmen in fortgeschrittener klinischer Phase, hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York am 7. und 8. Mai 2025 bekanntgegeben. CEO und Vorsitzender Thomas Zindrick sowie CFO Matt Pulisic werden am 8. Mai um 13:30 Uhr ET an einem Fireside-Chat mit Silvan Tuerkcan, Managing Director von Biotech Equity Research, teilnehmen. Die Diskussion wird sich auf die klinischen Programme des Unternehmens und bevorstehende Meilensteine konzentrieren.
Die Veranstaltung wird per Webcast zugänglich sein, mit einer Wiederholung, die für 90 Tage auf der IR-Seite von Genelux verfügbar ist. Das Unternehmen wird während der Konferenz auch Einzelgespräche mit institutionellen Investoren führen.
- None.
- None.
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York.
The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Ph1b evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) presenting at the Citizens Life Sciences Conference 2025?
Who will represent Genelux (GNLX) at the Citizens Life Sciences Conference?
What topics will Genelux (GNLX) discuss at the Citizens Life Sciences Conference?
How can investors access Genelux's (GNLX) presentation at the Citizens Life Sciences Conference?
